ROSEN, LEADING INVESTOR COUNSEL, Encourages Tricida Inc. Investors to Secure Counsel Before Important March 8 Deadline – TCDA
February 18, 2021 20:15 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Tricida, Inc. (NASDAQ: TCDA) between September 4, 2019 and...
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Tricida Inc. Investors with Losses Over $100K to Secure Counsel Before Important March 8 Deadline – TCDA
February 15, 2021 12:18 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 15, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Tricida, Inc. (NASDAQ: TCDA) between September 4, 2019 and...
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Reminds Fortress Biotech, Inc. Investors of Important Deadline in Securities Class Action - FBIO
January 08, 2021 19:15 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019...
ROSEN, A LEADING AND LONGSTANDING FIRM, Reminds Minerva Neurosciences, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NERV
January 08, 2021 17:08 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017...
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action – ZSAN
November 18, 2020 13:08 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13,...
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
September 24, 2020 07:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has submitted a New Drug Application...
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
September 23, 2020 19:30 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has submitted a New Drug Application...
FDA Approves SCENESSE® For Genetic Disorder
October 08, 2019 19:11 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which...
Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia
June 19, 2019 07:30 ET
|
Melinta Therapeutics
~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October...
FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance
June 25, 2018 06:00 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, June 25, 2018 (GLOBE NEWSWIRE) -- In a landmark case, the US Food and Drug Administration (FDA) has begun a review of an innovative drug developed for patients who carry a rare...